In this study, we have assessed the clinical value and feasibility of sensitive screening for the two most common BCL2 resistance mutations, G101V and D103Y, in a cohort of patients with R/R CLL outside of clinical trials receiving single-agent or venetoclax plus rituximab combination therapy. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.